ArticleRegenerative biomaterials2025
Mitochondria-targeting nanomedicines with autophagy inhibitor to enhance cancer photothermal-chemotherapy.
Article in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Mitochondria-Targeted Au@Carbon Dot Nanoprobes for SERS Analysis of Drug-Induced Mitophagy.Chemical & biomedical imaging · 2026Article
- Multifunctional Shape-Memory Polyurethane/MnOMaterials (Basel, Switzerland) · 2026Article
- [Exploration and application of nanotechnology in precision transarterial chemoembolization for hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Autophagy initiation inhibition combined with chemotherapy reverses drug resistance in oral cancer.Discover oncology · 2026Review
- Recent Advances in Mitochondria-Targeted Nano-Drug Delivery Systems for Cancer Therapy.International journal of nanomedicine · 2026Review
- Biomimetic lung-targeting vehicle coupled with cryo-shocked leukocyte and inflammation-anchored liposome for drug delivery and anti-inflammation in treatment of acute pneumonia.Regenerative biomaterials · 2026Article
- Nanoparticle Drug Delivery Systems: The Future Direction for the Treatment of Tumors.International journal of nanomedicine · 2026Review
- Photothermal and cascade ROS generative multilayer as intraocular lens surface coating for effective posterior capsular opacification inhibition.Regenerative biomaterials · 2026Article
- Advanced bone-targeted nanomaterials for the systemic treatment of osteoporosis.Regenerative biomaterials · 2026Review
- Multifunctional gold nanoparticles: bridging detection, diagnosis, and targeted therapy in cancer.Molecular cancer · 2025Review
- Advancements in Tumor-Targeted Nanoparticles: Design Strategies and Multifunctional Therapeutic Approaches.Nanomaterials (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this article, we fabricated nanomedicines with mitochondrial targeting function and autophagy inhibitor for enhancing cancer photothermal-chemotherapy. The nanoparticles were fabricated with gold nanoparticles (AuNPs) as cores and amphiphilic dextran with (3-carboxypropyl) triphenyl phosphorus bromide and β-cyclodextrin (β-CD) modification (TPP-DCD) as shells; the chemotherapeutic doxorubicin (DOX) and autophagy inhibitor chloroquine (CQ) were encapsulated in the nanoparticles. The TPP-DCD was synthesized via the immobilization of 2-aminoethanethiol modified β-CD and (3-carboxypropyl) triphenylphosphonium bromide on dextran to receive coordination interaction with AuNPs and mitochondria targeting. The size, morphology and properties of the Au@DOX/CQ@TPP-DCD nanoparticles were studied. The nanomedicines efficiently targeted cellular mitochondria to produce reactive oxygen species and photothermal effect under NIR irradiation. The released DOX and CQ could not only kill tumor cells directly, but also inhibit the autophagy of cancer cells to enhance therapeutic effects. Both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.